E-Therapeutics plc, of Oxford, UK, said an investigator-led Phase I trial testing synthetic cannibinoid ETS2101 in brain cancer will continue into 2014. Five dose-escalation steps have been completed without any drug-related serious adverse events and further patients are expected to be enrolled at higher dose levels.